 Primary objective of the study is to evaluate the correlation between level of HER2-neu gene amplification evalued by dual-color Fluorescent in-situ hybridization FISH test and time to progression TTP in patients with HER2-positive advanced breast cancer treated with trastuzumab-containing regimens. 